Babylon Health sells majority of UK assets to eMed
05 Sep 2023
Acquisition
Preview
Source: mobihealthnews
Photo: EDWIN TAN/Getty Images
Babylon Healthcare Services Limited, the piece of Babylon purchased by eMed and the bulk of what remained of Babylon Health, includes a U.K.-based telehealth practice focused on preventative care that contracts with healthcare providers. Financial terms of the sale were not disclosed.
The company's app G.P. at Hand, which provides primary health services to NHS customers in London and is still operating, is not part of the sale.
According to an SEC filing, "The sale will provide financial stability and allow [Babylon] to positively impact the lives of many more people within the U.K. and carry on exploring innovative approaches to proactive healthcare."
THE LARGER TREND
Babylon Health has struggled after going public through a $4.2 billion special purpose acquisition company merger with Alkuri Global Acquisition in 2021.
Its stock price has become worthless, with a market cap of just over $5,000 and a current trading value of $0.00020 per share.
In May, Babylon announced its plans to go private, announcing it accepted a take-private proposal from AlbaCore Capital on behalf of its affiliate MindMaze. The deal included a secured term loan facility for up to $34.5 million and Babylon's transition from a publicly traded company to a private entity. Babylon also planned to merge with MindMaze.
However, last month, Babylon reported the deal with MindMaze was not moving forward, and the company would pursue the sale of its U.K. business to third parties and exit its U.S. business.
Babylon subsequently filed for bankruptcy protection in Delaware last month for two U.S. subsidiaries, Babylon Inc. and Babylon Healthcare Inc., as it sought to liquidate its assets.
Tags: Babylon, Babylon Health, eMed, MindMaze
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.